SPOTLIGHT -
Guardant360 CDx Receives Companion Diagnostic Designation in ESR1+ Breast Cancer
The FDA has approved Guardant 360 CDx as a companion diagnostic for elacestrant in patients with ESR1-mutant, estrogen receptor–positive, HER2-negative advanced or metastatic breast cancer.
FDA Grants Approval to Elacestrant for ER+/HER2– Advanced Metastatic Breast Cancer
Patients with estrogen receptor–positive, HER2-negative metastatic breast cancer can now receive elacestrant as treatment following the FDA’s approval of the agent.
